Comorbidity and Schizophrenia: December 2018

3.00 CME
180 MINS
$30 FEE
SAVE
Psych Annals December 2018 Cover

Overview

Table of Contents

The NIMH Research Domain Criteria Initiative and Comorbidity in Schizophrenia: Research Implications

Jean-Pierre Lindenmayer, MD

Obsessive-Compulsive Schizophrenia: Clinical and Conceptual Perspective

Michael Hwang, MD; Ashvin Sood, MD; Burhan Riaz, BS; and Michael Poyurovsky, MD

Comorbid Obsessive-Compulsive Symptoms in Schizophrenia: Neurocognitive Profile

Won-Gyo Shin, PhD; Junhee Lee, MD; Tae Young Lee, MD; Danielle S. Himelfarb, MD; and Jun Soo Kwon, MD

Comorbid Schizophrenia and Panic Anxiety: Panic Psychosis Revisited

Jeffrey P. Kahn, MD; Tatiane Bombassaro, MSc; and Andre B. Veras, MD, PhD


Sponsorship Statement

This CME activity is jointly sponsored by AKH Inc., Advancing Knowledge in Healthcare and Psychiatric Annals.


Support Statement

There is no commercial support for this activity.


Learning Objectives

1. Describe the Research Domain Criteria framework, its fi ve domains, and its application to the assessment and biological underpinnings of comorbid disorders of schizophrenia.

2. Understand the phenomenology, pathogenesis, and management of comorbid obsessive-compulsive disorder in schizophrenia.

3. Describe the relationship between comorbid obsessive-compulsive schizophrenia and cognitive function in schizophrenia.

4. Understand the diagnosis, phenomenology, and treatment of comorbid schizophrenia and panic anxiety.

Faculty names and affiliations:  See authors above

Guest Editors: Michael Hwang, MD; and Peter F. Buckley, MD

Reviewer names:  Andrew A. Nierenberg, MD, Editor and Lenard A. Adler, MD, CME Coordinator, Psychiatric Annals


Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears at the beginning of each CME-accredited article in this issue and also on this page.

Faculty members report the following financial relationships:   Andrew A. Nierenberg, MD, has disclosed the following relevant financial relationships: Appliance Computing Inc. (Mindsite); Astra Zeneca; Brain Cells, Inc.; Brandeis University; Bristol Myers Squibb; Clintara, Dianippon Sumitomo/Sepracor; Eli Lilly and Company; EpiQ, Forest; Johnson and Johnson; Labopharm; Merck; Methylation Science; Novartis; PamLabs; PGx Health; Shire; Schering-Plough; Sunovion; Takeda/Lundbeck Pharmaceuticals; Targacept; Teva: Consultant. APSARD; Belvoir Publishing; Boston Center for the Arts; University of Texas Southwestern Dallas; Hillside Hospital; American Drug Utilization Review; American Society for Clinical Psychopharmacology; Bayamon Region Psychiatric Society; Baystate Medical Center; Canadian Psychiatric Association; Columbia University; Douglas Hospital/McGill University; IMEDEX; International Society for Bipolar Disorders; Israel Society for Biological Psychiatry; John Hopkins University; MJ Consulting; Massachusetts Association of College Counselors; Medscape; MBL Publishing; Physicians Postgraduate Press; Ryan Licht Sang Foundation; Slack Publishing; SUNY Buffalo; University of Florida; University of Miami; University of Wisconsin; University of Pisa; SciMed: Honoraria / travel expenses. Appliance Computing, Inc.; Brain Cells, Inc.: Stock options. AHRQ; Cephalon; Forest; Mylan; NIMH; PamLabs; Pfizer Pharmaceuticals; Takeda; Elan; Shire: Grant / research support.
Lenard A. Adler has disclosed the following relevant financial relationships: research grants paid to New York University (NYU) on Dr. Adler’s behalf from Sunovion Pharmaceuticals, Shire Pharmaceuticals, Lundbeck, Enzymotec, Purdue Pharma; personal fees for consulting or advisory boards from Sunovion Pharmaceuticals, Enzymotec, Shire Pharmaceuticals, the National Football League, Major League Baseball, Shire Pharmaceuticals, Otsuka Pharmaceuticals, Alcobra Pharmaceuticals; and royalty fees from NYU School of Medicine for license of Adult ADHD rating scales and training materials

Authors report the following financial relationships: Peter F. Buckley has no relevant financial relationships to disclose. Jean-Pierre Lindenmayer has no relevant financial relationships to disclose. Michael Hwang has no relevant financial relationships to disclose. Ashvin Sood has no relevant financial relationships to disclose. Burhan Riaz has no relevant financial relationships to disclose. Michael Poyurovsky has no relevant financial relationships to disclose. Won-Gyo Shin has no relevant financial relationships to disclose. Junhee Lee has no relevant financial relationships to disclose. Tae Young Lee has no relevant financial relationships to disclose. Danielle S. Himelfarb has no relevant financial relationships to disclose. Jun Soo Kwon has no relevant financial relationships to disclose. Jeffrey P. Kahn has no relevant financial relationships to disclose. Tatiane Bombassaro has no relevant financial relationships to disclose. Andre B. Veras has no relevant financial relationships to disclose.


Accreditation statement(s)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and SLACK Incorporated. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.


Credit Designation

AKH Inc., Advancing Knowledge in Healthcare designates this enduring material for a maximum of 3 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Release date:  December 1, 2018. Expiration Date:  January 1, 2022.


How to Participate

To participate in this CME activity, you must read the learning objectives, answer the pretest questions, read the articles, complete the CME posttest, and complete the evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, AKH Inc., Advancing Knowledge in Healthcare will issue an AMA PRA Category 1 Credit(s)™ certificate.


Target Audience

This CME activity is primarily targeted to patient-caring psychiatrists, physicians specializing in psychiatry and others allied to the field. There are no specific background requirements for participants taking this activity. Learning objectives and author disclosures are found at the beginning of each CME article.


Unlabeled and Investigational Usage Statement

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.


Copyright Statement

Copyright © 2018 by SLACK Incorporated. All rights reserved. No part of this publication may be reproduced without prior written consent of the publisher.